Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

meprevir
Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive, worldwide marketing rights, except for in the Nordic countries. Medivir will retain marketing rights for simeprevir in these countries. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C. To date, more than 3,700 patients have been treated with simeprevir in clinical trials.

Additionally, simeprevir is being studied in combination with several direct-acting antiviral agents (DAAs) with different mechanisms of action, with and without ribavirin, as part of interferon-free regimens. These include:

  • The Phase 2 COSMOS study of simeprevir and Gilead's nucleotide polymerase inhibitor sofosbuvir (GS-7977) in treatment-naive and previous null-responder genotype 1 HCV patients, including patients with cirrhosis; 
  • A Phase 2 study of simeprevir and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir in treatment-naive and previous null-responder genotype 1 HCV patients; 
  • The Phase 2 HELIX-1 study of simeprevir and Idenix's once-daily pan-genotypic NS5A inhibitor samatasvir (IDX719) in treatment-naive genotype 1b and genotype 4 HCV patients.

For additional information about simeprevir, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne in
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... SOUTH SAN FRANCISCO, Calif., March 2 Hana,Biosciences ... an Independent Data Monitoring,Committee (IDMC) has completed a ... ongoing pivotal rALLy clinical trial of Marqibo(R) (vincristine,sulfate ... lymphoblastic,leukemia (ALL) in second relapse. The results ...
... (ASX: PXS, Nasdaq: PXSL ) today announced ... the U.S. Food and Drug Administration (FDA) for Aridol, ... to help in the correct diagnosis and assessment of ... was based on a pre-NDA meeting with the FDA ...
Cached Medicine Technology:Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 2Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 4Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 5Pharmaxis Announces New Drug Application Submission for Aridol(TM) 2Pharmaxis Announces New Drug Application Submission for Aridol(TM) 3
(Date:5/6/2015)... has opened press registration for TU-Automotive Detroit as the ... headlines of major publications world-wide. With 150+ speakers from ... to share their visions for the future of connected ... to go behind the scenes and hear major automakers’ ... year we’re releasing a preview of all the major ...
(Date:5/6/2015)... Water NSW (New South ... manage and distribute imagery, LiDAR, and Elevation Data within ... driest continents on earth, and the need to ensure ... erratic seasonal rainfalls has driven the development of several ... manages raw water supplies for NSW, including high quality ...
(Date:5/6/2015)... May 06, 2015 Cloud security companies ... announced a strategic partnership to help small-to-medium businesses secure ... two industry-leading companies are teaming up to transition SafeMonk ... , “We’re thrilled to welcome SafeMonk users to the ... the people behind SafeMonk, the global powerhouse SafeNet (now ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... 2015 Most people in the United States ... other care after age 65. But less than half of ... or even talking about it, reports the May 2015 ... two problems. One is losing control over the care they'll ... Dr. David Grabowski, a professor of health care policy at ...
Breaking Medicine News(10 mins):Health News:Press Registration for TU-Automotive Detroit Now Open 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2
... concern over discrepancies in official data for key sectors ... called for a revamp of the national statistical system ... the administrative set up and traditional records, the (statistical) ... changing times," Manmohan Singh said in his address at ...
... the Institute Pasteur has recently shown that the tuberculosis ... fat cells. //This formidable pathogen is protected against even ... it may remain dormant for years. ,This ... possible strategies for fighting tuberculosis. Attempts to eradicate the ...
... research centre is being planned at the Pune-based ... diseases//, a general says. ,"Stem cell therapy ... will be the futuristic treatment replacing drug therapy ... diabetes, Parkinson's disease, epilepsy, multiple sclerosis, eye and ...
... San Diego biologists have shown that the chemical language ... electrical activity in the developing nervous system. The findings ... as a treatment for a wide range of brain ... the early on-line edition of the journal Proceedings of ...
... Christmas is indeed a ‘ubiquitous’ festival, as it is celebrated ... an estimated 26 million Indian homes.// The joys of the ... are seen making the most of the special bargains and ... time for the celebration. Plans are afoot in great enthusiasm ...
... director of Clarkson's Center for Air Resources Engineering ... on airborne pollution who serves on the Environmental ... also one of scores of health officials and ... the casual link between pollutants and respiratory illnesses. ...
Cached Medicine News:Health News:Manmohan Calls for Statistical Reforms in Healthcare and Education 2Health News:Tuberculosis: The Bacillus Takes Refuge in Adipose Cells 2Health News:Military College to Set Up Stem Cell Research Centre 2Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Research on to Find Link Between Airborne Pollutants and Respiratory Illness 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... ACUSON brand, the new Antares system, ... system that provides highly upgradeable and ... workflow efficiencies, and user-friendly ergonomics. ,The ... upon the advanced workflow and diagnostic ...
Medicine Products: